Reumatologia Clinica最新文献

{"title":"Clinical implications of persistent joint pain after gout flare","authors":"Wei Liu ,&nbsp;Peng Dong ,&nbsp;Chunyan Li ,&nbsp;Wen Guo ,&nbsp;Kaiping Zhao ,&nbsp;Siliang Man ,&nbsp;Liang Zhang ,&nbsp;Husheng Wu ,&nbsp;Hui Song","doi":"10.1016/j.reuma.2024.03.002","DOIUrl":"10.1016/j.reuma.2024.03.002","url":null,"abstract":"<div><h3>Objectives</h3><p>A subset of gout patients developed persistent joint pain after flares. Analysis of this clinical phenomenon may shed further light on the factors related to worsening gout and even provide clues to its pathogenesis.</p></div><div><h3>Methods</h3><p>We analyzed the clinical, laboratory, and ultrasound data of gout patients to explore the associations of these data with persistent joint pain after gout flares.</p></div><div><h3>Results</h3><p>A total of 1029 gout patients were included: 182 (17.7%) patients with persistent joint pain and 847 (82.3%) patients with nonpersistent joint pain. Patients with persistent joint pain had more total involved joints, more gout flares in the past year, and more joints with simultaneous gout flares (<em>P</em> <!-->&lt;<!--> <!-->0.01). Among the ultrasound-detected lesions, patients with persistent joint pain had a higher incidence of tophus (36.4% <em>vs.</em> 21.1%) and bone erosion (18.6% <em>vs.</em> 8.6%) (<em>P</em> <!-->&lt;<!--> <!-->0.05). Higher UA and lower TBil were found in patients with persistent joint pain (<em>P</em> <!-->&lt;<!--> <!-->0.001). Hypertension (54.9% <em>vs.</em> 38.7%) and metabolic syndrome (58.8% <em>vs.</em> 46.4%) were both more frequent in patients with persistent joint pain (<em>P</em> <!-->&lt;<!--> <!-->0.05). TBil was negatively correlated with the incidence of persistent joint pain (<em>P</em> <!-->&lt;<!--> <!-->0.001, <em>r</em> <!-->=<!--> <!-->−0.190), UA values (<em>P</em> <!-->&lt;<!--> <!-->0.001, <em>r</em> <!-->=<!--> <!-->−0.125), and metabolic syndrome scores (<em>P</em> <!-->&lt;<!--> <!-->0.001, <em>r</em> <!-->=<!--> <!-->−0.192). A correlation curve was fitted using LOESS (locally weighted region).</p></div><div><h3>Conclusion</h3><p>Persistent joint pain after gout flares is a marker of increased disease burden in gout. The significance of the level of total bilirubin for the exacerbation of gout deserves further study.</p></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140777892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of the image and corporate identity of the Colegio Mexicano de Reumatologia: Is it time to redefine it?","authors":"Jorge Luis Guzman-Serratos ,&nbsp;Raúl Daniel Martinez-Ramirez ,&nbsp;Ismael Gutierrez-Jimenez ,&nbsp;Alicia Vargas-Amésquita ,&nbsp;Francisco Javier Aceves-Avila ,&nbsp;Cesar Ramos-Remus","doi":"10.1016/j.reuma.2024.02.003","DOIUrl":"https://doi.org/10.1016/j.reuma.2024.02.003","url":null,"abstract":"<div><h3>Introduction and objectives</h3><p>The Colegio Mexicano de Reumatología (CMR) is a corporation whose brand has two elements—image and identity—that differentiate it from other corporations. We evaluated aspects of CMR's corporate image and identity.</p></div><div><h3>Subjects and methods</h3><p>To assess corporate image, we designed a survey using proof-of-concept and discrete-choice-experiments approaches. It assessed which definition (orthopedist, rheumatologist, or rehabilitator) was most meaningful in four pain scenarios in healthy adults from the country's Western region.</p><p>We used discourse analysis and five readability indices of the CMR website to assess corporate identity.</p></div><div><h3>Results</h3><p>In total, 700 respondents were included. For every rheumatologist chosen in the hand scenario, respondents chose 1.13 orthopedists and 0.70 rehabilitators. For every rheumatologist chosen in the knee scenario, respondents chose 2.36 orthopedists and 0.64 rehabilitators, whereas 0.85 orthopedists and 0.58 rehabilitators were chosen in the arthritis scenario. Only 38% of the respondents preferred the CMR's definition of a rheumatologist to describe a rheumatologist.</p><p>The younger age group preferred orthopedists to rheumatologists (50% vs. 31%, <em>p</em> <!-->&lt;<!--> <!-->0.001). In the arthritis scenario, the choice of rheumatologist increased from 27% in the elementary school group to 49% in the university group (<em>p</em> <!-->&lt;<!--> <!-->0.001). Mother was the most influential in healthcare seeking.</p><p>The discursive analysis revealed that the CMR is positioned as a “we” restricted to “colleagues;” the patient did not have agentive representation. The semiotic structure of the CMR's mission/vision was deemed imprecise and lacking in statements of value and purpose; the readability scores indicated that the text was challenging and dry.</p></div><div><h3>Conclusions</h3><p>The CMR's corporate image does not differentiate it from other health providers. CMR's identity seems ambiguous with restricted directionality. It seems pertinent to redefine the CMR.</p></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141435177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Approach to interstitial lung disease associated with systemic sclerosis—A survey to pulmonologists and rheumatologists in Colombia","authors":"Javier Leonardo Galindo ,&nbsp;Olga Milena García ,&nbsp;Diana Rocío Gil ,&nbsp;Luis Javier Cajas ,&nbsp;Emily Rincón-Álvarez ,&nbsp;Manuela Rubio","doi":"10.1016/j.reuma.2024.02.004","DOIUrl":"10.1016/j.reuma.2024.02.004","url":null,"abstract":"<div><h3>Introduction</h3><p>Interstitial lung disease is a leading cause of mortality in patients with systemic sclerosis. Currently, there is a lack of consensus regarding screening, rescreening, diagnosis, and follow-up practices in interstitial lung disease associated with systemic sclerosis (SSc-ILD) in Colombia.</p></div><div><h3>Methods</h3><p>A structured survey focused on clinical practices in patients with SSc-ILD was conducted. Members of the Asociación Colombiana de Neumología y Cirugía de Tórax (Asoneumocito) and the Asociación Colombiana de Reumatología (Asoreuma) were invited to participate from March 2023 to May 2023.</p></div><div><h3>Results</h3><p>We surveyed 51 pulmonologists and 44 rheumatologists. Overall, 51.6% reported having access to multidisciplinary team discussion in ILD. Among the 95 participants, 78.9% would routinely perform a high-resolution computed tomography scan of the chest once a diagnosis of systemic sclerosis was established. This practice is more frequent among rheumatologists (84.1%) than among pulmonologists (74.5%). Approximately half of the participants would rescreen patients annually with computed tomography scan (56.8%) if baseline images were negative.</p><p>Spirometry (81.1%), diffusing capacity of the lung for carbon monoxide (80.0%), and 6-min walk test (55.8%) were the most frequently performed tests upon diagnosis of systemic sclerosis. During follow-up, participants would consider repeating pulmonary function tests mostly every 6 months.</p></div><div><h3>Conclusions</h3><p>Screening of SSc-ILD is high among pulmonologists and rheumatologists. Decision-making on diagnosis and follow-up is similar between specialties, but there are variations in their frequency and indications. Further research is needed to evaluate how to adapt recommendations for assessing SSc-ILD in different settings.</p></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140797131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum leukemia inhibitory factor (LIF) levels in patients with Takayasu's and Giant cell arteritis: A cross-sectional study","authors":"Rahime Aksoy ,&nbsp;Tahsin Murat Turgay ,&nbsp;Recep Yilmaz ,&nbsp;Serdar Sezer ,&nbsp;Müçteba Enes Yayla ,&nbsp;Emine Uslu Yurteri","doi":"10.1016/j.reuma.2024.02.005","DOIUrl":"https://doi.org/10.1016/j.reuma.2024.02.005","url":null,"abstract":"<div><h3>Introduction and objectives</h3><p>In this study, we aimed to evaluate LIF levels and its possible relationship with disease activity in patients with Takayasu's (TAK) and Giant cell arteritis (GCA) patients.</p></div><div><h3>Materials and methods</h3><p>23 Takayasu's arteritis, 9 Giant cell arteritis patients and 25 healthy volunteers were included in the study. Serum LIF levels were measured ELISA.</p></div><div><h3>Results</h3><p>The mean age of Giant cell arteritis patients was statistically significantly higher than the other groups (<em>p</em> <!-->&lt;<!--> <!-->0.001). The rate of women was found to be higher in Takayasu's arteritis (<em>p</em> <!-->=<!--> <!-->0.021). When healthy control, patients with GCA and Takayasu arteritis were compared, there was a difference in LIF values (<em>p</em> <!-->=<!--> <!-->0.018). In subgroup analyzes, LIF values were found to be higher in GCA patients compared to healthy controls (<em>p</em> <!-->&lt;<!--> <!-->0.05). There was no statistically significant correlation between LIF and CRP (Rho<!--> <!-->=<!--> <!-->−0.038, <em>p</em> <!-->=<!--> <!-->0.778), ESR (Rho<!--> <!-->=<!--> <!-->0.114, <em>p</em> <!-->=<!--> <!-->0.399) and ITAS (Rho<!--> <!-->=<!--> <!-->−0.357, <em>p</em> <!-->=<!--> <!-->0.094). While CRP was statistically significantly higher in patients with disease activity (<em>p</em> <!-->=<!--> <!-->0.003), there was no statistically significant difference between patients in terms of ESR and LIF values. While there was a statistically significant relationship between CRP (OR<!--> <!-->=<!--> <!-->1.19 [1.03–1.37], <em>p</em> <!-->=<!--> <!-->0.018) and disease activity in univariate analyses, no statistically significant variable was found in multivariable analyses.</p></div><div><h3>Conclusions</h3><p>LIF values were significantly higher in patients with Giant cell arteritis compared to healthy controls.</p></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141435143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Elaboración de un protocolo asistencial en el embarazo y las artritis inflamatorias crónicas, en un grupo de trabajo multidisciplinar","authors":"Andrea Pluma ,&nbsp;Laia Alsina ,&nbsp;Estefanía Moreno ,&nbsp;Rafael Touriño ,&nbsp;Manel Casellas ,&nbsp;Dolors Grados ,&nbsp;Grup de Treball de Societat Catalana de Reumatologia FEMCAT","doi":"10.1016/j.reuma.2024.03.003","DOIUrl":"https://doi.org/10.1016/j.reuma.2024.03.003","url":null,"abstract":"<div><h3>Objective</h3><p>To design a care protocol in chronic inflammatory arthritis during the pre-conceptional period, pregnancy, postpartum and lactation. This protocol aims to be practical and applicable in consultations where patients with chronic inflammatory rheumatological diseases are treated, thus helping to better control these patients. Likewise, recommendations are offered on when patients could be consulted/referred to a specialized center by the physician.</p></div><div><h3>Methods</h3><p>A multidisciplinary panel of expert physicians from different specialties identified the key points, analyzed the scientific evidence, and met to develop the care protocol.</p></div><div><h3>Results</h3><p>The recommendations prepared have been divided into three blocks: rheumatology, gynecology and pediatrics. The first block has been divided into pre-pregnancy, pregnancy and postpartum visits.</p></div><div><h3>Conclusions</h3><p>This protocol tries to homogenize the follow-up of the patients from the moment of the gestational desire until the year of life of the infants. It is important to perform tests in patients of childbearing age and use drugs compatible with pregnancy. If appropriate, the patient should be referred to specialized units. Multidisciplinarity (rheumatology, gynecology and pediatrics) is essential to improve the control and monitoring of these patients and their offspring.</p></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141435176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Síndrome de VEXAS: a propósito de una serie de 2 casos","authors":"Adrián Mayo-Juanatey ,&nbsp;María José Fernández-Llavador ,&nbsp;María del Mar Fernández-Garcés ,&nbsp;Elia Valls-Pascual ,&nbsp;Juan José Alegre-Sancho","doi":"10.1016/j.reuma.2024.05.003","DOIUrl":"https://doi.org/10.1016/j.reuma.2024.05.003","url":null,"abstract":"<div><p>VEXAS syndrome is a rare entity secondary to UBA1 gene mutations, located on the X chromosome. This mutation generates, as a consequence, a characteristic vacuolation on haematopoietic stem-cells. It is characterized by multiple autoinflammatory and haematologic manifestations, which respond and end up being dependent on corticosteroid treatment. In this publication we present a 2-case series diagnosed at our hospital and make a brief literature review of the published evidence so far.</p></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141435182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Índice de autores","authors":"","doi":"10.1016/S1699-258X(24)00066-4","DOIUrl":"https://doi.org/10.1016/S1699-258X(24)00066-4","url":null,"abstract":"","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1699258X24000664/pdfft?md5=f27118a83a10f6a5cd402cc6e47769b8&pid=1-s2.0-S1699258X24000664-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141095361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Actualización de las Guías para el Tratamiento Farmacológico de la Artritis Reumatoide del Colegio Mexicano de Reumatología 2023","authors":"Carlos Abud-Mendoza ,&nbsp;Francisco Javier Aceves-Ávila ,&nbsp;César Alejandro Arce-Salinas ,&nbsp;José Álvarez Nemegyei ,&nbsp;Leonor Barile-Fabris ,&nbsp;Sergio Durán-Barragán ,&nbsp;Diana Elsa Flores-Alvarado ,&nbsp;Eufrates Hernández-Núñez ,&nbsp;Fedra Irazoque-Palazuelos ,&nbsp;José Francisco Moctezuma-Ríos ,&nbsp;Virginia Pascual-Ramos ,&nbsp;Margarita Portela-Hernández ,&nbsp;Luis Humberto Silveira ,&nbsp;Lilia Andrade-Ortega ,&nbsp;Ana Barrera-Vargas ,&nbsp;Sandra Carrillo-Vázquez ,&nbsp;Zully Castro-Colin ,&nbsp;Enrique Cuevas-Orta ,&nbsp;Luis Felipe Flores-Suárez ,&nbsp;Guillermo Arturo Guaracha-Basáñez ,&nbsp;César Pacheco-Tena","doi":"10.1016/j.reuma.2024.02.002","DOIUrl":"10.1016/j.reuma.2024.02.002","url":null,"abstract":"<div><h3>Objective</h3><p>To develop updated guidelines for the pharmacological management of rheumatoid arthritis (RA).</p></div><div><h3>Methods</h3><p>A group of experts representative of different geographical regions and various medical services catering to the Mexican population with RA was formed. Questions based on Population, Intervention, Comparison, and Outcome (PICO) were developed, deemed clinically relevant. These questions were answered based on the results of a recent systematic literature review (SLR), and the evidence's validity was assessed using the GRADE system, considered a standard for these purposes. Subsequently, the expert group reached consensus on the direction and strength of recommendations through a multi-stage voting process.</p></div><div><h3>Results</h3><p>The updated guidelines for RA treatment stratify various therapeutic options, including different classes of DMARDs (conventional, biologicals, and JAK inhibitors), as well as NSAIDs, glucocorticoids, and analgesics. By consensus, it establishes the use of these in different subpopulations of interest among RA patients and addresses aspects related to vaccination, COVID-19, surgery, pregnancy and lactation, and others.</p></div><div><h3>Conclusions</h3><p>This update of the Mexican guidelines for the pharmacological treatment of RA provides reference points for evidence-based decision-making, recommending patient participation in joint decision-making to achieve the greatest benefit for our patients. It also establishes recommendations for managing a variety of relevant conditions affecting our patients.</p></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140764337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pósteres: P200-P299","authors":"","doi":"10.1016/S1699-258X(24)00063-9","DOIUrl":"https://doi.org/10.1016/S1699-258X(24)00063-9","url":null,"abstract":"","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141094895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Junta Directiva de la SER, Comité de Organización de Congresos, Comité Científico del Congreso y Comité Organizador Local del Congreso","authors":"","doi":"10.1016/S1699-258X(24)00058-5","DOIUrl":"https://doi.org/10.1016/S1699-258X(24)00058-5","url":null,"abstract":"","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1699258X24000585/pdfft?md5=b7d147f2f3cb7a2fca4d8730541b13f1&pid=1-s2.0-S1699258X24000585-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141095518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}